These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 7662991)

  • 21. Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects.
    Sykes M; Harty MW; Szot GL; Pearson DA
    Blood; 1994 May; 83(9):2560-9. PubMed ID: 7909457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
    Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
    Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation.
    Min CK; Maeda Y; Lowler K; Liu C; Clouthier S; Lofthus D; Weisiger E; Ferrara JL; Reddy P
    Blood; 2004 Nov; 104(10):3393-9. PubMed ID: 15280194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease.
    Alpdogan O; Schmaltz C; Muriglan SJ; Kappel BJ; Perales MA; Rotolo JA; Halm JA; Rich BE; van den Brink MR
    Blood; 2001 Oct; 98(7):2256-65. PubMed ID: 11568014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism of protection from graft-versus-host disease mortality by IL-2. III. Early reductions in donor T cell subsets and expansion of a CD3+CD4-CD8- cell population.
    Abraham VS; Sachs DH; Sykes M
    J Immunol; 1992 Jun; 148(12):3746-52. PubMed ID: 1534824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Flt3 ligand (FL) treatment of murine donors does not modify graft-versus-host disease (GVHD) but FL treatment of recipients post-bone marrow transplantation accelerates GVHD lethality.
    Blazar BR; McKenna HJ; Panoskaltsis-Mortari A; Taylor PA
    Biol Blood Marrow Transplant; 2001; 7(4):197-207. PubMed ID: 11349806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The identification and characteristics of IL-22-producing T cells in acute graft-versus-host disease following allogeneic bone marrow transplantation.
    Zhao K; Zhao D; Huang D; Song X; Chen C; Pan B; Wu Q; Cao J; Yao Y; Zeng L; Xu K
    Immunobiology; 2013 Dec; 218(12):1505-13. PubMed ID: 23816304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice.
    Murphy WJ; Welniak LA; Taub DD; Wiltrout RH; Taylor PA; Vallera DA; Kopf M; Young H; Longo DL; Blazar BR
    J Clin Invest; 1998 Nov; 102(9):1742-8. PubMed ID: 9802888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A decrease in graft-vs.-host disease without loss of graft-vs.-leukemia reactivity after MHC-matched bone marrow transplantation by selective depletion of donor NK cells in vivo.
    Johnson BD; Truitt RL
    Transplantation; 1992 Jul; 54(1):104-12. PubMed ID: 1631918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Host reactive donor T cells are associated with lung injury after experimental allogeneic bone marrow transplantation.
    Cooke KR; Krenger W; Hill G; Martin TR; Kobzik L; Brewer J; Simmons R; Crawford JM; van den Brink MR; Ferrara JL
    Blood; 1998 Oct; 92(7):2571-80. PubMed ID: 9746799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of the additional injection of host-type bone marrow on the immune tolerance of minor antigen-mismatched chimeras: possible involvement of double-negative (natural killer) T cells.
    Sefrioui H; Billiau AD; Overbergh L; Rutgeerts O; Waer M
    Transplantation; 1999 Nov; 68(10):1560-7. PubMed ID: 10589955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects.
    Reddy P; Teshima T; Hildebrandt G; Williams DL; Liu C; Cooke KR; Ferrara JL
    Blood; 2003 Apr; 101(7):2877-85. PubMed ID: 12433681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytokine profiles in various graft-versus-host disease target organs following hematopoietic stem cell transplantation.
    Lai HY; Chou TY; Tzeng CH; Lee OK
    Cell Transplant; 2012; 21(9):2033-45. PubMed ID: 22840591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD; Becker EE; Truitt RL
    Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
    Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
    J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lethal murine graft-versus-host disease induced by donor gamma/delta expressing T cells with specificity for host nonclassical major histocompatibility complex class Ib antigens.
    Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Barrett TA; Bluestone JA; Vallera DA
    Blood; 1996 Jan; 87(2):827-37. PubMed ID: 8555509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Donor gamma delta T lymphocytes promote allogeneic engraftment across the major histocompatibility barrier in mice.
    Drobyski WR; Majewski D
    Blood; 1997 Feb; 89(3):1100-9. PubMed ID: 9028343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation.
    MacDonald KP; Rowe V; Filippich C; Thomas R; Clouston AD; Welply JK; Hart DN; Ferrara JL; Hill GR
    Blood; 2003 Mar; 101(5):2033-42. PubMed ID: 12393418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamic regulation of effector IFN-γ-producing and IL-17-producing T cell subsets in the development of acute graft-versus-host disease.
    Zhao K; Ruan S; Yin L; Zhao D; Chen C; Pan B; Zeng L; Li Z; Xu K
    Mol Med Rep; 2016 Feb; 13(2):1395-403. PubMed ID: 26647759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.